Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma

Abstract excerpt

Abstract Children with ependymoma (EPN) are cured in less than 50% of cases, with little improvement in outcome over the last several decades. Chemotherapy has not affected survival in EPN, due in part to a lack of preclinical models that has precluded comprehensive drug testing. We recently developed two human EPN cell lines harboring high-risk phenotypes which provided us with an opportunity to execute...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer therapeutics and mechanisms
• Share to Glioma Diagnosis and Treatment
• Share to PARP inhibition in cancer therapy